secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2025-06-06T23:59:59+00:00
Accession:  0001437749-25-019719
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Aytu BioPharma prices $14.4M upsized public offering of common stock and prefunded warrants
--------------------------------------------------------------------------------

- Priced upsized public offering of 9,600,000 shares of common stock (or prefunded warrants) at $1.50 per share.
- Granted underwriters 30-day option to purchase up to additional 1,440,000 shares of common stock.
- Net proceeds of approximately $12.9M (or $14.9M if option exercised) to be used for general corporate purposes and to exclusively commercialize EXXUA (gepirone) for major depressive disorder.
- Offering expected to close June 9, 2025; Lake Street Capital Markets acting as sole book runner.
- Maxim Group LLC acting as lead manager and Ascendiant Capital Markets as financial advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925019719/0001437749-25-019719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925019719/aytu20250605_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-019719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer